This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Nintedanib for Systemic Sclerosis Associated Interstitial Lung Disease

< Back

Nintedanib for Systemic Sclerosis Associated Interstitial Lung Disease


Respiratory Disease and Thoracic Surgery

January 2018

Systemic Sclerosis (Scleroderma or SSc) is an uncommon condition that results in hard, thickened areas of skin and sometimes problems with the internal organs and blood vessels. This condition is caused by the immune system attacking the areas under the skin and around internal organs and blood vessels called connective tissue. This causes scarring and thickening in these areas. SSc affects the lungs of about half of the people with the condition. Inflammation and scarring of the lung tissue is called interstitial lung disease (ILD). The most common presenting symptom of ILD is difficult breathing on exertion. Other indicators of ILD may include non-productive cough, fatigue and chest pain. Many patients with SSc become less physically active because of musculoskeletal complaints or the fatiguing nature of the illness. Lung involvement in all its forms in patients with SSc has emerged to be the leading cause of death and disability.
Nintedanib (OFEV®) is a medicine that is being developed for the treatment of Systemic Sclerosis associated interstitial lung disease (SSc-ILD). It acts by targeting the specific mechanisms by which scarring of the lungs occur, reducing progression of the disease. It is given by mouth as capsules. Nintedanib (as OFEV) is already available in the EU for the treatment of idiopathic pulmonary fibrosis (IPF). Because SSc-ILD and IPF share similarities in how the underlying lung scarring, or fibrosis, forms in people with the disease, the development of nintedanib for the treatment of SSc-ILD may address unmet needs. If licensed, nintedanib may offer an additional treatment option (the first licensed) for patients with SSc-ILD.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts